GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (ASX:TRI) » Definitions » EV-to-EBITDA

TrivarX (ASX:TRI) EV-to-EBITDA : -3.54 (As of May. 20, 2024)


View and export this data going back to 2001. Start your Free Trial

What is TrivarX EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TrivarX's enterprise value is A$12.04 Mil. TrivarX's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.40 Mil. Therefore, TrivarX's EV-to-EBITDA for today is -3.54.

The historical rank and industry rank for TrivarX's EV-to-EBITDA or its related term are showing as below:

ASX:TRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.38   Med: -2.81   Max: 0.64
Current: -3.54

During the past 13 years, the highest EV-to-EBITDA of TrivarX was 0.64. The lowest was -16.38. And the median was -2.81.

ASX:TRI's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Healthcare Providers & Services industry
Industry Median: 12.935 vs ASX:TRI: -3.54

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), TrivarX's stock price is A$0.03. TrivarX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.020. Therefore, TrivarX's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


TrivarX EV-to-EBITDA Historical Data

The historical data trend for TrivarX's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX EV-to-EBITDA Chart

TrivarX Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -1.58 -8.02 -0.26 -1.76

TrivarX Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.26 - -1.76 -

Competitive Comparison of TrivarX's EV-to-EBITDA

For the Health Information Services subindustry, TrivarX's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TrivarX's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TrivarX's EV-to-EBITDA falls into.



TrivarX EV-to-EBITDA Calculation

TrivarX's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12.040/-3.401
=-3.54

TrivarX's current Enterprise Value is A$12.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TrivarX's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TrivarX  (ASX:TRI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

TrivarX's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.03/-0.020
=At Loss

TrivarX's share price for today is A$0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TrivarX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


TrivarX EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of TrivarX's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


TrivarX (ASX:TRI) Business Description

Traded in Other Exchanges
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.